Clinical Effects of Moxifloxacin and Levofloxacin in the Treatment of Elderly Patients with Community-Acquired Pneumonia  

作　　者：Shi Chen Yan Gao Zhilan Ji Wenwen Lin 

机构地区：[1]The Second People’s Hospital of Binhai County,Yancheng 224500,Jiangsu Province,China

出　　处：《Journal of Clinical and Nursing Research》2024年第12期171-177,共7页临床护理研究（英文）

摘　　要：Objective:To compare the clinical efficacy of moxifloxacin and levofloxacin in the treatment of elderly patients with community-acquired pneumonia(CAP).Methods:A total of 80 elderly CAP patients admitted between April 2023 and February 2024 were randomly divided into two groups.The control group(n=40)received treatment with levofloxacin,while the observation group(n=40)was treated with moxifloxacin.Relevant clinical indicators were observed and compared between the two groups.Results:The overall effective treatment rate in the observation group reached 95.00%,significantly higher than the 75.00%observed in the control group(P<0.05).The time required for improvement in clinical symptoms was significantly shorter in the observation group compared to the control group(P<0.001).Pulmonary function indicators,including FVC,FEV1,and FEV1/FVC,improved in both groups after treatment,but the improvement was more pronounced in the observation group(P<0.001).Serum inflammatory factor levels indicated that post-treatment levels of IL-6,PCT,and CRP decreased in both groups compared to pre-treatment levels,with a more significant reduction in the observation group(P<0.001).The incidence of adverse reactions in the observation group was 7.50%,markedly lower than the 25.00%observed in the control group(P<0.05).Conclusion:Moxifloxacin demonstrates better clinical efficacy and safety in the treatment of elderly patients with CAP,making it a valuable option for clinical application.However,the choice of medication should still consider individual patient conditions comprehensively.

关 键 词：MOXIFLOXACIN LEVOFLOXACIN Elderly community-acquired pneumonia Clinical efficacy 

分 类 号：R73[医药卫生—肿瘤]